When did Iovance Biotherapeutics, Inc. report Q4 2024 earnings?

Iovance Biotherapeutics, Inc. (IOVA) reported Q4 2024 earnings on February 27, 2025 after market close.

What were Iovance Biotherapeutics, Inc.'s Q4 2024 revenue and EPS?

Iovance Biotherapeutics, Inc. reported revenue of $73.7M and eps of $-0.26 for Q4 2024.

Did Iovance Biotherapeutics, Inc. beat estimates in Q4 2024?

Revenue beat the consensus estimate of $72.2M by $1.5M. EPS beat the consensus estimate of $-0.26 by $0.00.

Where can I find Iovance Biotherapeutics, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0001558370-25-001834) directly on SEC EDGAR. The filing index links above go to sec.gov.

Iovance Biotherapeutics, Inc. IOVA Q4 2024 Annual earnings

Reported February 27, 2025 · After market close

Revenue$73.7MBeat by $1.5M

EPS-$0.26In line

Revenue estimate$72.2M

EPS estimate-$0.26

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$87.7M

EPS estimate-$0.17

Financials

Q4 2024

Income statement

See full

Revenue$73.7M+15,189%

Gross profit$35.9M+515%

Operating income-$86.6M+28.6%

Net income-$78.6M+32.5%

EPS (diluted)-$0.25+44.4%

Balance sheet

See full

Cash & equivalents$115.7M-36.2%

Total debt$58.3M-23.2%

Total equity$710.4M+21.5%

Total assets$910.4M+16.7%

Cash flow

See full

Operating cash flow-$73.3M+12.7%

CapEx$4.2M+18.1%

Free cash flow-$77.5M+11.5%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$2.26B+8.4%

Enterprise value$2.2B+11.3%

P/S13.7×-1,736×

Profitability

See full

Gross margin34.2%+21.1pp

Operating margin-240.9%-120pp

Net margin-226.8%-113pp

FCF margin-221.9%-111pp

Returns & leverage

See full

Return on equity-57.5%-13.2pp

Debt / equity0.1×0.0×

Current ratio3.7×+0.9×

Segments

By product

See full

Amtagvi$48.7M—

Proleukin$25.0M+5,083%

By segment

See full

Single Reportable$73.7M+24,692%

By geography

See full

US$73.2M—

Versus estimates

Revenue

Q1 2026$71.4MMiss by $6.4M Q4 2025$86.7MBeat by $6.0M Q3 2025$67.5MMiss by $14.7M Q2 2025$60.0MMiss by $18.4M Q1 2025$49.3MMiss by $33.1M

Q4 2024$73.7MBeat by $1.5M

Diluted EPS

Q1 2026-$0.19In line Q4 2025-$0.18Beat by $0.04 Q3 2025-$0.25Beat by $0.04 Q2 2025-$0.33Miss by $0.04 Q1 2025-$0.36Miss by $0.11

Q4 2024-$0.26In line

Ask the moment Iovance Biotherapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Iovance Biotherapeutics, Inc. report Q4 2024 earnings?: Iovance Biotherapeutics, Inc. (IOVA) reported Q4 2024 earnings on February 27, 2025 after market close.
What were Iovance Biotherapeutics, Inc.'s Q4 2024 revenue and EPS?: Iovance Biotherapeutics, Inc. reported revenue of $73.7M and eps of $-0.26 for Q4 2024.
Did Iovance Biotherapeutics, Inc. beat estimates in Q4 2024?: Revenue beat the consensus estimate of $72.2M by $1.5M. EPS beat the consensus estimate of $-0.26 by $0.00.
Where can I find Iovance Biotherapeutics, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001558370-25-001834) directly on SEC EDGAR. The filing index links above go to sec.gov.